English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

All nephrologists are well aware of the high prevalence of ARVD, especially in older populations, its association with extrarenal atherosclerotic disease and its high mortal- ity. Data from US Medicare show that patients with ARVD have an ∼3-fold increased mortality compared to those Medicare recipients without the condition (2), and that over the 12-year period, 1992-2004, there was an ∼4-fold alence of moderate or severe diastolic dysfunction (93% vs. 46%) and higher filling pressures than those without heart failure. Although no coronary angiographic valida- tion was available, the authors reasonably speculated that the high rate of diastolic heart failure in the patients was likely to have resulted from the long-standing or severe hy- pertension which invariably was present. The presence of these echocardiographic abnormalities and of the clinical heart failure diagnosis was associated with a 2.9 increased risk of mortality compared to patients without heart failure, with 1- and 5-year mortality being 23% vs. 8%, and 73% vs. 35%, respectively, and heart failure conferred a dou- bling of the risk of progressing to end-stage renal disease (ESRD). The only systematic echocardiographic studies in

Renal revascularization for heart failure in patients with atherosclerotic renovascular disease